Sunday, November 8, 2026

At Least 48 Taken to Hospitals Over Suspicions of Anthrax Outbreak in Turkey

Cagri Akyurt

September 10, 2018

A cow of Turkish Natıve Black Cattle breed. Photo by: Zeynel Cebeci.
ANKARA, Turkey (ViaNews) - According to the reports from the ministry of health, some cities in the southeast of the country and a facility in Istanbul has been quarantined following the increase of anthrax patients. Fahrettin Koca, Minister of Health told in a written statement: “48 people, who were in contact with cattle suspected to be infected by anthrax were sent to our facilities for examination. Six of these people were confirmed to develop skin lesions, which is a symptom of anthrax infection.” According to the Minister of Forestry and Agriculture, two neighbourhoods of Istanbul’s Silivri district were quarantined and more than 3000 animals were vaccinated as a precaution. There were similar reports from Ankara and Sivas as well. Authorities detected that cattle imported from Brazil to Meat and Milk Institution were infected with anthrax. After the sudden death of more than 140 animals on a farm in Ankara, authorities detected signs of anthrax, leading them to kill the animals and keep the farm under quarantine. A few days later a family of three from Sivas was hospitalized for anthrax suspicion after eating an infected animal. According to Demirören News Agency, the family butchered their animal after its sudden death, before they recognized the symptoms. While the daughter and the father are discharged from the hospital, the son is still being kept in quarantine.

Categories

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com